mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma

Prostate cancer patients with localized disease are treated with curative intent. However, the disease will recur in approximately 30% of patients with a high incidence of morbidity and mortality. Prognostic biomarkers are needed to identify patients with high risk of relapse. mTOR pathway activatio...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Stelloo, Suzan, Sanders, Joyce, Nevedomskaya, Ekaterina, de Jong, Jeroen, Peters, Dennis, van Leenders, Geert J.L.H., Jenster, Guido, Bergman, Andries M., Zwart, Wilbert
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2016
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5078062/
https://ncbi.nlm.nih.gov/pubmed/27096957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8767
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak